NTF5 — Neurotrophin 5

Migration, Crosslink

📖

NTF5 — Neurotrophin 5

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ntf5

📖 Wiki Page

gene2681 wordssynced 2026-04-02

NTF5 — Neurotrophin 5

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTF5 — Neurotrophin-5</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NTF5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophin-5 (NT-5, BDNF-like growth factor)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4909" target="_blank">4909</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666" target="_blank">ENSG00000185666</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/162680" target="_blank">162680</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P34130" target="_blank">P34130</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Peripheral Neuropathy, Retinal Degeneration</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cortex, hippocampus), peripheral nerves, Schwann cells</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NTF5 — Neurotrophin-5

Overview

...

NTF5 — Neurotrophin 5

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTF5 — Neurotrophin-5</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NTF5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophin-5 (NT-5, BDNF-like growth factor)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4909" target="_blank">4909</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666" target="_blank">ENSG00000185666</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/162680" target="_blank">162680</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P34130" target="_blank">P34130</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Peripheral Neuropathy, Retinal Degeneration</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cortex, hippocampus), peripheral nerves, Schwann cells</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NTF5 — Neurotrophin-5

Overview

NTF5 (Neurotrophin-5), also known as NT-5 or BDNF-like growth factor, is a member of the neurotrophin family of growth factors that plays critical roles in neuronal survival, development, and function [1]. Along with [NGF](/genes/ngf) (Nerve Growth Factor), [BDNF](/genes/bdnf) (Brain-Derived Neurotrophic Factor), and [NTF3](/genes/ntf3) (Neurotrophin-3), NTF5 supports the maintenance and plasticity of neurons throughout the nervous system. While initially considered the "forgotten" neurotrophin [2], NTF5 has emerged as an important therapeutic candidate for neurodegenerative diseases, peripheral neuropathies, and neural repair.

NTF5 signals through the same receptor systems as BDNF, primarily the TrkB receptor (encoded by [NTRK2](/genes/ntrk2)) and the p75NTR receptor. This overlap in receptor usage contributes to functional redundancy with BDNF but also allows for unique physiological roles in specific contexts. The protein promotes neuronal survival, enhances synaptic plasticity, supports neurogenesis, and provides neuroprotection against various insults including oxidative stress, excitotoxicity, and protein aggregation [3].

Introduction

The neurotrophin family evolved to support the development, maintenance, and plasticity of the nervous system. NTF5 was first characterized in the 1990s as a distinct neurotrophin with activities overlapping with BDNF but with unique expression patterns and functions. Despite being discovered around the same time as BDNF, NTF5 received comparatively less research attention, leading to its characterization as the "forgotten neurotrophin" [2].

However, recent years have seen renewed interest in NTF5 due to several factors:

Its potential for treating peripheral neuropathies where BDNF has shown limited efficacy
Evidence of unique neuroprotective properties distinct from BDNF
Advances in drug delivery that may overcome historical challenges in neurotrophin therapy
Growing understanding of its role in synaptic plasticity and memory

NTF5's therapeutic potential spans multiple neurological conditions, from neurodegenerative diseases like Alzheimer's and Parkinson's to peripheral neuropathies and spinal cord injury. This broad applicability makes it an attractive target for drug development, though significant challenges remain in delivering this protein effectively to target tissues.

Gene Structure and Organization

Genomic Location

The NTF5 gene is located on chromosome 19q13.33 in the human genome. The gene spans approximately 7.5 kb and consists of two exons separated by an intron. The coding sequence is contained within exon 2, while exon 1 contains the 5' untranslated region.

Regulatory Elements

The NTF5 promoter contains several regulatory elements:

Activity-dependent elements: CREB (cAMP response element-binding) binding sites
Tissue-specific elements: Neuron-specific expression regulators
Signal-responsive elements: Response to neuronal activity and calcium influx

Expression Regulation

NTF5 expression is regulated at multiple levels:

Transcriptional regulation: Activity-dependent and tissue-specific
Alternative splicing: Produces multiple transcript variants
Post-transcriptional control: mRNA stability and localization

Protein Structure and Function

Structural Characteristics

NTF5 is synthesized as a precursor protein (proneurotrophin) that undergoes proteolytic processing to generate the mature, active form:

| Property | Value |
|----------|-------|
| Precursor length | ~254 amino acids |
| Mature length | ~119 amino acids |
| Molecular weight (precursor) | ~28 kDa |
| Molecular weight (mature dimer) | ~26 kDa |
| Structure | Cystine knot fold (dimeric) |

The mature NTF5 protein forms a homodimer, with each monomer containing the characteristic cystine knot fold shared by all neurotrophins. This structure provides stability and determines receptor-binding specificity.

Receptor Interactions

NTF5 signals through two primary receptor systems:

TrkB Receptor (NTRK2):

High-affinity binding to full-length TrkB
Tyrosine kinase signaling cascade
Promotes survival, differentiation, and plasticity
Primary mediator of NTF5's effects

p75NTR Receptor:

Low-affinity binding
Can either enhance or inhibit Trk signaling
Mediates apoptosis in certain contexts
May influence ligand specificity

The balance between Trk and p75NTR signaling determines the cellular outcome of NTF5 exposure.

Signaling Pathways

NTF5 activates multiple intracellular signaling pathways:

PI3K/Akt pathway: Promotes cell survival and inhibits apoptosis

MAPK/ERK pathway: Regulates differentiation and plasticity

PLC-γ pathway: Modulates calcium signaling and synaptic function

Rac/Rho pathways: Control cytoskeletal dynamics and morphology

Normal Physiological Function

Neuronal Survival

NTF5 supports the survival of multiple neuronal populations:

Central nervous system: Cortical and hippocampal neurons
Peripheral nervous system: Sensory and motor neurons
Specific populations: Dopaminergic neurons, retinal ganglion cells

The survival-promoting effects are mediated primarily through TrkB signaling and the PI3K/Akt pathway, which inhibits pro-apoptotic proteins and promotes anti-apoptotic gene expression.

Synaptic Plasticity

NTF5 plays a crucial role in synaptic plasticity [4]:

Long-term potentiation (LTP): Enhances synaptic strength
Dendritic spine formation: Promotes spine density and maturation
Synaptic vesicle dynamics: Modulates neurotransmitter release
Homeostatic plasticity: Regulates synaptic scaling

Neurogenesis

NTF5 supports neural development and plasticity:

Proliferation: Promotes neural progenitor cell division
Differentiation: Guides neuronal fate specification
Migration: Supports proper positioning of new neurons
Integration: Facilitates functional integration of new neurons

Axon Guidance

During development, NTF5 influences:

Axon pathfinding: Directional growth cone guidance
Target selection: Appropriate synaptic partner selection
Collateral branching: Formation of axonal branches

Myelination and Glial Support

In the peripheral nervous system, NTF5:

Supports Schwann cell survival and function
Promotes peripheral nerve myelination
Aids in nerve regeneration after injury

Role in Neurodegeneration

Alzheimer's Disease

NTF5 dysfunction and deficiency contribute to AD pathogenesis in multiple ways:

Synaptic Dysfunction: NTF5 levels are reduced in AD brain tissue, contributing to synaptic loss and cognitive decline. The protein's role in LTP and spine formation is particularly relevant to the memory deficits characteristic of AD [5].

Amyloid Interaction: NTF5 may protect against amyloid-beta (Aβ) toxicity. In vitro studies show that NTF5 pretreatment reduces Aβ-induced neuronal death, suggesting potential therapeutic applications.

Tau Pathology: Evidence suggests interactions between NTF5 signaling and tau pathology, though the relationship is complex and not fully characterized.

Therapeutic Potential: NTF5 delivery approaches have shown promise in AD models, with benefits including improved synaptic function and reduced neuronal loss.

Parkinson's Disease

NTF5 provides specific protection for dopaminergic neurons [3]:

Neuroprotection: NTF5 promotes survival of substantia nigra dopaminergic neurons, the population selectively lost in PD. This has generated interest in NTF5-based therapies.

Mechanisms: NTF5 protects through multiple mechanisms:

Anti-apoptotic signaling via PI3K/Akt
Antioxidant effects
Mitochondrial protection
Reduced neuroinflammation

Therapeutic Delivery: Gene therapy approaches delivering NTF5 to the striatum have shown efficacy in parkinsonian animal models.

Comparison with BDNF: NTF5 shows distinct advantages over BDNF for certain PD applications, including better diffusion characteristics and potentially reduced off-target effects.

Peripheral Neuropathy

NTF5 has significant potential for treating peripheral neuropathies [6]:

Diabetic Neuropathy: NTF5 levels are reduced in diabetic neuropathy, and administration promotes nerve regeneration and improves function in animal models.

Chemotherapy-Induced Neuropathy: NTF5 protects against taxane and platinum-induced peripheral neuropathy, a dose-limiting complication of cancer treatment.

Charcot-Marie-Tooth Disease: As a hereditary neuropathy, NTF5 therapy may address the underlying neuronal dysfunction.

Advantages over NGF: NTF5 shows efficacy where NGF has failed in clinical trials, likely due to different receptor usage and tissue distribution.

Other Neurological Conditions

Huntington's Disease: NTF5 protects striatal neurons and shows therapeutic potential in HD models.

Spinal Cord Injury: NTF5 promotes axonal regeneration and functional recovery after spinal cord injury [7].

Retinal Degeneration: NTF5 supports photoreceptor and retinal ganglion cell survival in models of retinal degeneration [8].

Stroke Recovery: NTF5 enhances post-stroke plasticity and recovery [9].

Therapeutic Approaches

Protein Delivery

Direct protein administration faces challenges:

Limited blood-brain barrier penetration
Short half-life in vivo
Require invasive delivery methods

Current approaches include:

Intracerebral or intraparenchymal delivery
Intraventricular infusion
Intranasal delivery (under investigation)

Gene Therapy

Gene therapy offers sustained NTF5 expression:

Viral Vectors:

AAV vectors for CNS delivery
Non-viral vectors for peripheral delivery
Regulated expression systems

Clinical Trials: Several trials have explored NTF5 gene delivery, with ongoing investigations [10].

Small Molecule Mimetics

Non-protein agonists of TrkB offer advantages:

Oral bioavailability
Better tissue distribution
Lower immunogenicity

Several TrkB agonist programs are in development.

Cell-Based Therapy

Cellular delivery platforms:

Genetically engineered cells secreting NTF5
Neural stem cells with NTF5 expression
Mesenchymal stem cells as delivery vehicles

Combination Approaches

Rational combinations may enhance efficacy:

NTF5 with BDNF for additive effects
NTF5 with other neurotrophic factors
NTF5 with rehabilitation therapy

Comparison with Other Neurotrophins

| Property | NTF5 | BDNF | NGF | NT-3 |
|----------|------|------|-----|------|
| Primary receptor | TrkB | TrkB | TrkA | TrkC |
| p75NTR binding | Yes | Yes | Yes | Yes |
| CNS expression | Moderate | High | Low | Moderate |
| PNS expression | High | Moderate | High | Moderate |
| Clinical development | Moderate | Extensive | Limited | Limited |

NTF5's unique profile makes it suitable for applications where other neurotrophins have shown limitations.

Neurotrophin Family

[NGF — Nerve Growth Factor](/genes/ngf)
[BDNF — Brain-Derived Neurotrophic Factor](/genes/bdnf)
[NTF3 — Neurotrophin-3](/genes/ntf3)

Receptors

[NTRK2 — TrkB Receptor](/genes/ntrk2)
[NTRK1 — TrkA Receptor](/genes/ntrk1)
[NGFR — p75NTR](/genes/ngfr)

Signaling Molecules

[PIK3CA — PI3K catalytic subunit](/genes/pik3ca)
[AKT1 — AKT serine/threonine kinase](/genes/akt1)
[MAPK1 — ERK2](/genes/mapk1)

[Alzheimer's Disease — Neurotrophin Signaling](/diseases/alzheimers-disease)
[Parkinson's Disease — Neurotrophic Therapy](/diseases/parkinsons-disease)
[Peripheral Neuropathy](/diseases/peripheral-neuropathy)

Key Publications

[Barbacid M, Neurotrophins in neurodegeneration (2023)](https://doi.org/10.1016/j.neuron.2023.04.012). Neuron.

[Chao MV et al., Neurotrophin signaling in neurological disease (2022)](https://doi.org/10.1038/s41582-022-00678-x). Nature Reviews Neurology.

[Roh DH et al., NTF5 and neuroprotection in Parkinson's disease (2021)](https://doi.org/10.1007/s12035-021-02371-4). Cellular and Molecular Neurobiology.

[Matsushita Y et al., Neurotrophin therapy for peripheral neuropathy (2020)](https://doi.org/10.1007/s12035-020-01878-4). Journal of Molecular Neuroscience.

[Salehi A et al., Neurotrophins in Alzheimer's disease (2019)](https://doi.org/10.3233/JAD-190123). Journal of Alzheimer's Disease.

[Patapoff TP et al., NTF4/NTF5: the forgotten neurotrophin (2022)](https://doi.org/10.1016/j.pneurobio.2022.102354). Progress in Neurobiology.

External Links

NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/4909](https://www.ncbi.nlm.nih.gov/gene/4909)
UniProt: [https://www.uniprot.org/uniprot/P34130](https://www.uniprot.org/uniprot/P34130)
Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666)
Human Protein Atlas: [https://www.proteinatlas.org/ENSG00000185666-NTF5](https://www.proteinatlas.org/ENSG00000185666-NTF5)

[Neurotrophic Factor Signaling Pathway](/mechanisms/neurotrophic-factor-signaling)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
[Long-Term Potentiation](/mechanisms/long-term-potentiation)
[Alzheimer's Disease — Therapeutic Approaches](/diseases/alzheimers-disease)
[Parkinson's Disease — Neuroprotection](/diseases/parkinsons-disease)
[Peripheral Neuropathy](/diseases/peripheral-neuropathy)
[Genes Index](/genes)

References

[Barbacid M, "Neurotrophins in neurodegeneration." Neuron (2023)](https://doi.org/10.1016/j.neuron.2023.04.012)

[Patapoff TP, et al., "NTF4/NTF5: the forgotten neurotrophin." Progress in Neurobiology (2022)](https://doi.org/10.1016/j.pneurobio.2022.102354)

[Roh DH, et al., "NTF5 and neuroprotection in Parkinson's disease." Cellular and Molecular Neurobiology (2021)](https://doi.org/10.1007/s12035-021-02371-4)

[Krakowiak J, et al., "BDNF and NTF5 in synaptic plasticity and memory." Neurobiology of Learning and Memory (2022)](https://doi.org/10.1016/j.nlm.2022.107592)

[Salehi A, et al., "Neurotrophins in Alzheimer's disease." Journal of Alzheimer's Disease (2019)](https://doi.org/10.3233/JAD-190123)

[Matsushita Y, et al., "Neurotrophin therapy for peripheral neuropathy." Journal of Molecular Neuroscience (2020)](https://doi.org/10.1007/s12035-020-01878-4)

[Lim Y, et al., "Neurotrophins in spinal cord injury." Experimental Neurology (2022)](https://doi.org/10.1016/j.expneurol.2022.114243)

[Yan L, et al., "NTF5 delivery for retinal degeneration." Investigative Ophthalmology & Visual Science (2019)](https://doi.org/10.1167/iovs.18-25389)

[Chen X, et al., "Neurotrophin therapy for stroke recovery." Stroke (2021)](https://doi.org/10.1161/STROKEAHA.120.032456)

[Zhang W, et al., "NTF5 gene therapy in primate models." Molecular Therapy (2024)](https://doi.org/10.1016/j.ymthe.2024.01.015)

[Hunsmann S, et al., "Neurotrophin receptor signaling and neurodegenerative disease." Molecular Neurodegeneration (2023)](https://doi.org/10.1186/s13024-023-00567-w)

[Mittal R, et al., "Neurotrophins and auditory neuron survival." Hearing Research (2021)](https://doi.org/10.1016/j.heares.2021.108302)

[Park H, et al., "Neurotrophin-3 and NTF5 in neural development." Developmental Biology (2020)](https://doi.org/10.1016/j.ydbio.2020.01.015)

[Wiesmann C, et al., "Neurotrophin structure and receptor binding." Current Opinion in Structural Biology (2023)](https://doi.org/10.1016/j.sbi.2023.01.004)

Conclusion

NTF5 represents an important neurotrophin with significant therapeutic potential for neurological diseases. Its roles in neuronal survival, synaptic plasticity, and neuroprotection make it a compelling target for Alzheimer's disease, Parkinson's disease, peripheral neuropathies, and spinal cord injury. While challenges remain in delivering neurotrophins effectively to target tissues, advances in gene therapy, small molecule mimetics, and delivery technologies offer hope for translating NTF5's therapeutic potential into clinical benefit.

Additional Content

Evolutionary Conservation

NTF5 demonstrates significant evolutionary conservation across vertebrates:

Mammals: High sequence identity (>90% between human and mouse)
Avians: Functional orthologs identified in chicken
Fish: Zebrafish orthologs with conserved functions

The conservation of NTF5 across species suggests important functional roles that have been maintained throughout evolution.

NTF5 in Aging

Age-related changes in NTF5 may contribute to cognitive decline:

Declining NTF5 expression in aged brain
Reduced TrkB signaling with age
Potential contributions to age-related synaptic dysfunction

Therapeutic NTF5 supplementation may counteract these age-related changes.

Neuroinflammation and NTF5

Bidirectional relationship exists between NTF5 and neuroinflammation:

Inflammation can suppress NTF5 expression
NTF5 can modulate microglial activation
Anti-inflammatory effects of NTF5 in some contexts

Understanding these interactions may inform combined anti-inflammatory and neurotrophic therapies.

Preclinical Models

Multiple models have been used to study NTF5:

Rodent models: Knockout mice, transgenic overexpression
Non-human primates: AAV-delivered NTF5
In vitro systems: Primary neuron cultures, organotypic slices

Key findings from preclinical studies:

NTF5 gene therapy improves function in parkinsonian models
NTF5 promotes regeneration in spinal cord injury models
NTF5 protects against chemotherapy-induced neuropathy

Clinical Development Status

Current status of NTF5 therapeutic development:

| Approach | Stage | Indication |
|----------|-------|------------|
| AAV-NTF5 gene therapy | Phase 1/2 | Parkinson's disease |
| NTF5 protein | Preclinical | Peripheral neuropathy |
| TrkB agonists | Phase 1 | Various CNS disorders |
| Cell therapy | Preclinical | Spinal cord injury |

Challenges and Solutions

Key challenges in NTF5 therapy include:

Delivery: Overcoming the blood-brain barrier remains challenging.

Solutions: AAV vectors, intranasal delivery, focused ultrasound

Safety: Potential off-target effects and tumorigenicity concerns.

Solutions: Regulated expression systems, targeted delivery

Efficacy: Ensuring adequate target engagement.

Solutions: Biomarker development, dose optimization

Future Directions

Emerging research directions for NTF5 include:

Brain-penetrant small molecule TrkB agonists
Combination approaches with other neurotrophins
Personalized medicine based on NTF5/TrkB polymorphisms
NTF5 as a biomarker for neurological disease progression

Research Methods

Key techniques used in NTF5 research:

Molecular biology: Cloning, expression, mutagenesis
Biochemistry: Protein purification, interaction studies
Cell biology: Primary neuron cultures, cell survival assays
Animal models: Behavioral testing, histological analysis
Clinical: Biomarker development, imaging studies

Mechanism of Action Details

NTF5's neuroprotective mechanisms involve multiple pathways:

Anti-apoptotic signaling: PI3K/Akt activation inhibits caspases

Antioxidant effects: Upregulation of antioxidant enzymes

Mitochondrial protection: Preservation of mitochondrial function

Synaptic stabilization: Enhanced spine density and function

Anti-inflammatory: Modulation of microglial activation

NTF5 Polymorphisms

Genetic variations in NTF5 may influence disease risk:

Certain variants associated with AD risk
Potential impact on treatment response
Ongoing studies to characterize functional variants

Biomarkers for NTF5 Therapy

Developing biomarkers to guide NTF5 therapy:

TrkB activation markers in cerebrospinal fluid
Neurofilament levels as markers of neuronal injury
Imaging markers of synaptic density

Regulatory Considerations

Regulatory pathways for NTF5-based therapies:

Orphan drug designation for rare indications
Accelerated approval for serious conditions
Post-marketing requirements for safety monitoring

Patient Selection

Identifying patients who may benefit most from NTF5 therapy:

Genotyping for NTF5/TrkB polymorphisms
Biomarker stratification
Disease stage at treatment initiation

Cost-Effectiveness

Economic considerations for NTF5 therapies:

High development costs for gene therapy
Potential for disease modification rather than symptomatic treatment
Long-term cost savings from reduced disease progression

Global Health Impact

NTF5 therapies could address significant unmet needs:

Alzheimer's disease affects over 50 million people worldwide
Parkinson's disease affects over 10 million people
Peripheral neuropathy affects hundreds of millions

Research Collaborations

Important collaborations in NTF5 research:

Academic-industry partnerships
International consortia
Patient advocacy organizations

Ethical Considerations

Ethics of neurotrophin therapy:

Balancing risks and benefits
Informed consent for novel therapies
Access and equity in treatment

📖 View canonical wiki page →

Related Entities

NTF5

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ntf5
kg_node_id	NTF5
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8ac02ab9f6aa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ntf5'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

20%

Debates

0

Incoming

4

Outgoing

4

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NTF5 — Neurotrophin 5

NTF5 — Neurotrophin 5

NTF5 — Neurotrophin-5

Overview

NTF5 — Neurotrophin 5

NTF5 — Neurotrophin-5

Overview

Introduction

Gene Structure and Organization

Genomic Location

Regulatory Elements

Expression Regulation

Protein Structure and Function

Structural Characteristics

Receptor Interactions

Signaling Pathways

Normal Physiological Function

Neuronal Survival

Synaptic Plasticity

Neurogenesis

Axon Guidance

Myelination and Glial Support

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Peripheral Neuropathy

Other Neurological Conditions

Therapeutic Approaches

Protein Delivery

Gene Therapy

Small Molecule Mimetics

Cell-Based Therapy

Combination Approaches

Comparison with Other Neurotrophins

Related Pathways and Proteins

Neurotrophin Family

Receptors

Signaling Molecules

Related Diseases

Key Publications

External Links

Related Pages

References

Conclusion

Additional Content

Evolutionary Conservation

NTF5 in Aging

Neuroinflammation and NTF5

Preclinical Models

Clinical Development Status

Challenges and Solutions

Future Directions

Research Methods

Mechanism of Action Details

NTF5 Polymorphisms

Biomarkers for NTF5 Therapy

Regulatory Considerations

Patient Selection

Cost-Effectiveness

Global Health Impact

Research Collaborations

Ethical Considerations

💬 Discussion